COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I REGNREGN LY-CoVLY RemdesivirRMD
HCQ study #66 of 230
6/22 Early treatment study
Chen et al., medRxiv, doi:10.1101/2020.06.19.20136093 (Preprint)
Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: a prospective open-label randomized controlled study
Source   PDF   Share   Tweet
Significantly faster clinical recovery and shorter time to RNA negative (from 7.0 days to 2.0 days (HCQ), p=0.01. 67 patients with mild/moderate cases.

Chen et al., 6/22/2020, Randomized Controlled Trial, China, Asia, preprint, 19 authors, dosage 200mg bid days 1-10.
median time to PCR-, 72.0% lower, relative time 0.28, p = 0.01, treatment 18, control 12.
Details of all 230 studies    Meta analysis
Please send us corrections, updates, or comments.
Submit